Last updated: May 5, 2024
Sponsor: HoHo Biotech
Overall Status: Active - Recruiting
Phase
2
Condition
Inflammation
Treatment
Hydrogen capsules
Clinical Study ID
NCT06401785
C202305150
Ages 20-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 20 to 80
- Able to compliant with the protocol
- Able to return to the hospital regularly
- Patients with chronic inflammation, including patients with autoimmune diseases,metabolic-related diseases, chronic kidney disease or nephritis, tumor patients, etc.
Exclusion
Exclusion Criteria:
- Pregnancy
- Expected pregnancy
- Attending other clinical trials with 6 months
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Hydrogen capsules
Phase: 2
Study Start date:
May 11, 2024
Estimated Completion Date:
January 29, 2025
Study Description
Connect with a study center
Tri-Service General Hospital
Taipei,
TaiwanActive - Recruiting
Taoyuan Armed Forces General Hospital
Taoyuan,
TaiwanActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.